Bile Duct Cancer Global Market Report 2025

The bile duct cancer market size has grown strongly in recent years. It will grow from $2.39 billion in 2024 to $2.6 billion in 2025 at a compound annual growth rate (CAGR) of 9.1%. The growth during the historic period can be attributed to greater exposure to toxic chemicals, increased awareness of bile duct cancer, a growing geriatric population, a rising incidence of bile duct and pancreatic cancers, and higher investments in healthcare infrastructure.

The bile duct cancer market size is expected to see strong growth in the next few years. It will grow to $3.63 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be driven by the increasing incidence of bile duct cancer, a rising number of cases of bile duct and liver cancer, a growing prevalence of biliary tract cancers (BTCs), an uptick in research and development activities, and a higher demand for advanced treatment options. Key trends include advancements in diagnostic techniques, innovations in medical technology, improvements in endoscopic imaging, ongoing technological innovations, and the expansion of personalized medicine approaches.

The increasing prevalence of liver diseases is anticipated to drive the growth of the bile duct cancer market. Liver diseases encompass a broad range of conditions that impair liver function, including hepatitis, cirrhosis, fatty liver disease, and liver cancer. The rising incidence of liver diseases is attributed to factors such as excessive alcohol consumption, unhealthy diets, obesity, viral infections (such as hepatitis B and C), and sedentary lifestyles. Bile duct cancer plays a crucial role in understanding liver diseases, as bile duct obstruction or dysfunction often leads to severe liver-related complications, including jaundice and cholestasis. For instance, in April 2024, according to The House of Commons Library, a UK-based government department, 10,593 individuals under the age of 75 in England died from liver disease in 2022, continuing the upward trend in mortality rates. The rate increased from 21.2 per 100,000 population in 2021 to 21.4 per 100,000 in 2022. Consequently, the growing prevalence of liver diseases is fueling the expansion of the bile duct cancer market.

Leading companies in the bile duct cancer market are investing in innovative targeted therapies to enhance treatment outcomes, minimize side effects, and offer new hope to patients facing this rare and complex cancer. Targeted therapies focus on specific genes, proteins, or molecular mechanisms that drive cancer growth, aiming to inhibit tumor progression while reducing systemic toxicity. For example, in August 2023, Taiho Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, introduced FGFR Inhibitor LYTGOBI Tablets 4mg. This oral formulation provides a convenient treatment option, improving patient compliance and ease of administration. LYTGOBI is designed for patients with advanced or metastatic bile duct cancer harboring FGFR2 fusion or rearrangement mutations, addressing a significant unmet need in cancer care.

In July 2023, Lucence, a US-based precision health company, partnered with Innovent Biologics Inc. to enhance molecular diagnostics for bile duct cancer in Hong Kong. Through this collaboration, Lucence aims to integrate Innovent Biologics' advanced targeted therapies into its diagnostic services, improving early detection and personalized treatment approaches for patients. Innovent Biologics Inc. is a China-based biotechnology company specializing in the development, manufacturing, and commercialization of innovative biopharmaceuticals.

Major players in the bile duct cancer market are AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Merck & Co. Inc., Boehringer Ingelheim International GmbH, Eisai Co. Ltd., Genentech Inc., Jazz Pharmaceuticals plc, Incyte Corporation, Exelixis Inc., Hutchison China MediTech Limited, Zymeworks Inc., Mirati Therapeutics Inc., RenovoRx Inc., Spectrum Pharmaceuticals Inc., Specialised Therapeutics Pty Ltd, Taiho Pharmaceutical Co. Ltd.

North America was the largest region in the bile duct cancer market in 2024. The regions covered in bile duct cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the bile duct cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Bile duct cancer is a rare malignancy that develops in the bile ducts, which transport bile from the liver to the gallbladder and small intestine. It is often diagnosed in advanced stages and can cause symptoms such as jaundice, weight loss, and abdominal pain.

The primary types of bile duct cancer include extrahepatic bile duct cancer (ECC) and intrahepatic bile duct cancer (ICC). ECC occurs in the bile ducts outside the liver, typically where they exit the liver and connect to the small intestine. Treatment options for ECC include surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy. It is categorized by stage into localized, regional, and distant forms, with diagnosis typically involving imaging tests, biopsy, and blood tests. These diagnostic and treatment approaches are utilized by various end users, including hospitals, clinics, ambulatory surgical centers, and cancer research institutes.

The bile duct cancer market research report is one of a series of new reports that provides bile duct cancer market statistics, including the bile duct cancer industry global market size, regional shares, competitors with the bile duct cancer market share, detailed bile duct cancer market segments, market trends, and opportunities, and any further data you may need to thrive in the bile duct cancer industry. This bile duct cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The bile duct cancer market includes revenues earned by entities by services such as diagnostic services, treatment services, clinical trials, and research services, and related products such as pharmaceutical products, diagnostic products, and supportive care products. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.